Mark Simon
Showing 1–2 of 2 transcripts.
- Milken Institute1h 2m
Solving Life-Threatening Problems in Oncology
Howard Soule, Rajiv Kaul, Freda Lewis-Hall, David Reese, Mark Simon, Howard Sewell
A panel of industry leaders including Pfizer's Dr. Freda Lewis-Hall and Amgen's David Reese examines the paradox of skyrocketing NIH funding and precision oncology breakthroughs against persistent barriers like clinical trial rigidity and healthcare inequities. The discussion highlights the disconnect between advanced "Star Wars" level treatments and outdated delivery systems, calling for regulatory agility and patient-centric trial designs to address the 2.1-fold increase in cancer-related bankruptcies. Ultimately, the experts urge a systemic shift toward democratizing access to genomic diagnostics and prioritizing quality-of-life endpoints over traditional longevity metrics.
- Milken Institute1h 1m
Bringing 21st Century Medicine to America's Veterans
Jonathan Simons, Matthew Collier, Magali Haas, Matthew Rettig, Mark Simon
The Department of Veterans Affairs has established a Senior Advisor for Strategic Partnerships to shift from isolated operations to a collaborative model leveraging its $169 billion budget and unique longitudinal data assets. By partnering with entities like Cohen Veterans Bioscience and private biotech firms, the agency is accelerating research on traumatic brain injury, suicide prevention, and precision oncology, evidenced by successful treatments for advanced prostate cancer patients. These initiatives aim to de-risk clinical trials, improve patient access to novel therapies, and transform the VA into a premier engine for precision medicine by overcoming historical cultural barriers to external collaboration.